Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 34 publications
CPX-351 (Liposomal Cytarabine and Daunorubicin) versus venetoclax plus hypomethylating agent therapy in newly diagnosed acute myeloid leukemia: a retrospective comparison involving 600 Mayo Clinic patients.
Journal: Blood cancer journal
Published: November 28, 2025
NGS-based monitoring of secondary acute lymphoblastic leukemia dynamics following lenalidomide maintenance in multiple myeloma patients.
Journal: Leukemia & lymphoma
Published: November 19, 2025
Eliminating REMS for CAR T-Cell Therapies: An Opportunity to Improve Access.
Journal: Cancers
Published: September 16, 2025
Acute leukemia of ambiguous lineage with KMT2A-alterations in adults.
Journal: Leukemia & lymphoma
Published: August 25, 2025
Applicability of current prognostication models for MDS patients with DDX41 mutation.
Journal: Leukemia research
Published: July 08, 2025
Systemic Mastocytosis in 910 Patients: Prognostic Contribution of the International Consensus Classification in the Context of the Mayo Alliance Prognostic System.
Journal: American journal of hematology
Published: May 19, 2025
Clinical Outcome and Molecular Profile in Patients with DDX41 Mutation Hot-Spots.
Journal: Hematology reports
Published: March 21, 2025
Validation of the 5th edition of the World Health Organization and International Consensus Classification guidelines for TP53-mutated myeloid neoplasm in an independent international cohort.
Journal: Blood cancer journal
Published: December 27, 2024
Mayo Genetic Risk Models for Newly Diagnosed Acute Myeloid Leukemia Treated With Venetoclax + Hypomethylating Agent.
Journal: American journal of hematology
Published: November 16, 2024
Evidence-based risk stratification of myeloid neoplasms harboring TP53 mutations.
Journal: Blood advances
Published: November 04, 2024
Last Updated: 09/26/2026